Kinoshita, Ryo Tokushima University|Kumamoto University
Ishima, Yu Tokushima University Tokushima University Educator and Researcher Directory
Chuang, Victor T. G. Curtin University
Watanabe, Hiroshi Kumamoto University
Shimizu, Taro Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ando, Hidenori Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Otagiri, Masaki Sojo University
Ishida, Tatsuhiro Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Maruyama, Toru Kumamoto University
human serum albumin
enhanced permeability and retention effect
Human serum albumin (HSA) is a versatile drug carrier with active tumor targeting capacity for an antitumor drug delivery system. Nanoparticle albumin-bound (nab)-technology, such as nab-paclitaxel (Abraxane®), has attracted significant interest in drug delivery research. Recently, we demonstrated that HSA dimer (HSA-d) possesses a higher tumor distribution than HSA monomer (HSA-m). Therefore, HSA-d is more suitable as a drug carrier for antitumor therapy and can improve nab technology. This study investigated the efficacy of HSA-d-doxorubicin (HSA-d-DOX) as next-generation nab technology for tumor treatment. DOX conjugated to HSA-d via a tunable pH-sensitive linker for the controlled release of DOX. Lyophilization did not affect the particle size of HSA-d-DOX or the release of DOX. HSA-d-DOX showed significantly higher cytotoxicity than HSA-m-DOX in vitro. In the SUIzo Tumor-2 (SUIT2) human pancreatic tumor subcutaneous inoculation model, HSA-d-DOX could significantly inhibit tumor growth without causing serious side effects, as compared to the HSA binding DOX prodrug, which utilized endogenous HSA as a nano-drug delivery system (DDS) carrier. These results indicate that HSA-d could function as a natural solubilizer of insoluble drugs and an active targeting carrier in intractable tumors with low vascular permeability, such as pancreatic tumors. In conclusion, HSA-d can be an effective drug carrier for the antitumor drug delivery system against human pancreatic tumors.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
|DOI (Published Version)|
|URL ( Publisher's Version )|
pharm_13_8_1209.pdf 10.9 MB